Last 12 months
Inside the activity.
0 purchase rows · 83 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 17 |
| Apr 2026 | 0 | 8 |
| May 2026 | 0 | 9 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 9 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 8 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2025 Filed Mar 18, 2025 00:23 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
SaleCommon Stock | 2,775 | $44.38 | $123,154.50 |
DisclosureSEC source: 0001127602-25-009712 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,888 F1 · kind: Sell to cover transaction in connection with the vesting of restricted stock units. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 00:21 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 4,389 | $44.38 | $194,783.82 |
DisclosureSEC source: 0001127602-25-009711 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,005 F1 · kind: Sell to cover transaction in connection with the vesting of restricted stock units. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 00:19 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 12,648 | $44.38 | $561,318.24 |
DisclosureSEC source: 0001127602-25-009710 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 326,533 F1 · kind: Sell to cover transaction in connection with the vesting of restricted stock units. Read SEC document |
| March 17, 2025 Filed Mar 17, 2025 20:36 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 25,000 | $44.65 | $1,116,250.00 |
DisclosureSEC source: 0001127602-25-009695 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 339,181 Read SEC document |
| March 17, 2025 Filed Mar 17, 2025 20:33 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 20,900 | $0.00 Strike: $23.26 | $0.00 |
DisclosureSEC source: 0001127602-25-009691 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,000 Underlying: Common Stock · 20,900 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| March 17, 2025 Filed Mar 17, 2025 20:33 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
SaleCommon Stock | 20,900 | $45.14 | $943,426.00 |
DisclosureSEC source: 0001127602-25-009691 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,663 Read SEC document |
| March 17, 2025 Filed Mar 17, 2025 20:33 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 20,900 | $23.26 | $486,134.00 |
DisclosureSEC source: 0001127602-25-009691 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2025 Filed Mar 15, 2025 00:53 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $23.26 | $0.00 |
DisclosureSEC source: 0001127602-25-009556 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,900 Underlying: Common Stock · 100 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| March 14, 2025 Filed Mar 15, 2025 00:53 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
SaleCommon Stock | 100 | $45.00 | $4,500.00 |
DisclosureSEC source: 0001127602-25-009556 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,663 Read SEC document |
| March 14, 2025 Filed Mar 15, 2025 00:53 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 100 | $23.26 | $2,326.00 |
DisclosureSEC source: 0001127602-25-009556 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:24 UTC |
Lee SungEVP, Chief Financial Officer
|
GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 41,326 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001127602-25-009770 · form4.xml · derivative · entry 3 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,326 Underlying: Common Stock · 41,326 shares Expires 2035-03-13 F3 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Mr. Lee's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:24 UTC |
Lee SungEVP, Chief Financial Officer
|
GrantIncentive Stock Option (Right to Buy) · Derivative | 9,016 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001127602-25-009770 · form4.xml · derivative · entry 2 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,016 Underlying: Common Stock · 9,016 shares Expires 2035-03-13 F2 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Mr. Lee's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:24 UTC |
Lee SungEVP, Chief Financial Officer
|
GrantCommon Stock | 32,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-009770 · form4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,442 F1 · kind: Comprised of restricted stock units that convert to shares of common stock on a 1:1 basis upon vesting. 40% of the RSUs will vest on the 1-year anniversary of the date of grant; an additional 40% of the RSUs will vest on the 2-year anniversary of the date of grant; and the final 20% of the RSUs will vest on the 3-year anniversary of the date of grant, in each case subject to Mr. Lee's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:20 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 47,593 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001127602-25-009765 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,593 Underlying: Common Stock · 47,593 shares Expires 2035-03-13 F3 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Mr. Callos's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:20 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
GrantIncentive Stock Option (Right to Buy) · Derivative | 2,749 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001127602-25-009765 · form4.xml · derivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,749 Underlying: Common Stock · 2,749 shares Expires 2035-03-14 F2 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Mr. Callos's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:20 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
GrantCommon Stock | 32,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-009765 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,350 F1 · kind: Comprised of restricted stock units that convert to shares of common stock on a 1:1 basis upon vesting. 40% of the RSUs will vest on the 1-year anniversary of the date of grant; an additional 40% of the RSUs will vest on the 2-year anniversary of the date of grant; and the final 20% of the RSUs will vest on the 3-year anniversary of the date of grant, in each case subject to Mr. Callos's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:17 UTC |
Malik Fady IbrahamEVP Research & Development
|
GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 58,465 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001127602-25-009760 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,465 Underlying: Common Stock · 58,465 shares Expires 2035-03-13 F3 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Dr. Malik's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:17 UTC |
Malik Fady IbrahamEVP Research & Development
|
GrantIncentive Stock Option (Right to Buy) · Derivative | 2,293 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001127602-25-009760 · form4.xml · derivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,293 Underlying: Common Stock · 2,293 shares Expires 2035-03-13 F2 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Dr. Malik's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:17 UTC |
Malik Fady IbrahamEVP Research & Development
|
GrantCommon Stock | 39,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-009760 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,844 F1 · kind: Comprised of restricted stock units that convert to shares of common stock on a 1:1 basis upon vesting. 40% of the RSUs will vest on the 1-year anniversary of the date of grant; an additional 40% of the RSUs will vest on the 2-year anniversary of the date of grant; and the final 20% of the RSUs will vest on the 3-year anniversary of the date of grant, in each case subject to Dr. Malik's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:08 UTC |
Blum Robert IDirector · President & CEO
|
GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 176,547 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001127602-25-009749 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,547 Underlying: Common Stock · 176,547 shares Expires 2035-03-13 F5 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Mr. Blum's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:08 UTC |
Blum Robert IDirector · President & CEO
|
GrantIncentive Stock Option (Right to Buy) · Derivative | 2,254 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001127602-25-009749 · form4.xml · derivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,254 Underlying: Common Stock · 2,254 shares Expires 2035-03-13 F4 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Mr. Blum's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:08 UTC |
Blum Robert IDirector · President & CEO
|
GrantCommon Stock | 116,096 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-009749 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,277 F1 · kind: Comprised of restricted stock units that convert to shares of common stock on a 1:1 basis upon vesting. 40% of the RSUs will vest on the 1-year anniversary of the date of grant; an additional 40% of the RSUs will vest on the 2-year anniversary of the date of grant; and the final 20% of the RSUs will vest on the 3-year anniversary of the date of grant, in each case subject to Mr. Blum's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 20:30 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
SaleCommon Stock | 26,771 | $43.62 | $1,167,751.02 |
DisclosureSEC source: 0001127602-25-009355 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,663 Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 01:43 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
SaleCommon Stock | 3,341 | $43.27 | $144,565.07 |
DisclosureSEC source: 0001127602-25-008792 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,434 F1 · kind: Sale to cover transaction in connection with the vesting of restricted stock units. Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 01:41 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 8,228 | $43.27 | $356,025.56 |
DisclosureSEC source: 0001127602-25-008791 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,394 F1 · kind: Sale to cover transaction in connection with the vesting of restricted stock units. Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 01:39 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 16,970 | $43.44 | $737,176.80 |
DisclosureSEC source: 0001127602-25-008790 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,181 F1 · kind: Sell to cover transaction in connection with vesting of restricted stock units. Read SEC document |
| March 05, 2025 Filed Mar 5, 2025 21:43 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 25,000 | $43.23 | $1,080,750.00 |
DisclosureSEC source: 0001127602-25-008331 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 381,151 Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 21:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-007915 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 21:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 2,000 | $42.50 | $85,000.00 |
DisclosureSEC source: 0001127602-25-007915 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,071 Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 21:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-007915 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 21:24 UTC |
Harrington Robert ArthurDirector
|
SaleCommon Stock | 900 | $42.50 | $38,250.00 |
DisclosureSEC source: 0001127602-25-007902 · form4.xml · nonDerivative · entry 1 Harrington Robert Arthur · CIK 0001923988 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,108 Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:39 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 2,449 | $42.88 | $105,013.12 |
DisclosureSEC source: 0001127602-25-008321 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,622 F1 · kind: Sale to cover transaction in relation to the vesting of restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:34 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 8,743 | $42.88 | $374,899.84 |
DisclosureSEC source: 0001127602-25-008312 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406,151 F1 · kind: Sale to cover transaction in relation to vesting of restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:37 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
SaleCommon Stock | 1,114 | $42.88 | $47,768.32 |
DisclosureSEC source: 0001127602-25-008316 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,775 F1 · kind: Sale to cover transaction in relation to vesting of restricted stock units. Read SEC document |
| February 18, 2025 Filed Feb 18, 2025 21:32 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-005237 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 18, 2025 21:32 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 2,000 | $45.98 | $91,960.00 |
DisclosureSEC source: 0001127602-25-005237 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,071 Read SEC document |
| February 18, 2025 Filed Feb 18, 2025 21:32 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-005237 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 13:26 UTC |
Landry Robert EDirector
|
GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 25,538 | $0.00 Strike: $42.21 | $0.00 |
DisclosureSEC source: 0001127602-25-003989 · form4.xml · derivative · entry 1 Landry Robert E · CIK 0001585160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,538 Underlying: Common Stock · 25,538 shares Expires 2035-02-12 F1 · kind: Initial grant to new director. Stock Options vest monthly over 3-years from the date of grant. Read SEC document |
| February 04, 2025 Filed Feb 4, 2025 21:31 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-002944 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2025 Filed Feb 4, 2025 21:31 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 2,000 | $48.06 | $96,120.00 |
DisclosureSEC source: 0001127602-25-002944 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,071 Read SEC document |
| February 04, 2025 Filed Feb 4, 2025 21:31 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-002944 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2025 Filed Jan 21, 2025 21:29 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-001636 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2025 Filed Jan 21, 2025 21:29 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 2,000 | $45.92 | $91,840.00 |
DisclosureSEC source: 0001127602-25-001636 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,071 Read SEC document |
| January 21, 2025 Filed Jan 21, 2025 21:29 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-001636 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:25 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-001059 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:25 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 2,000 | $49.32 | $98,640.00 |
DisclosureSEC source: 0001127602-25-001059 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,071 Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:25 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-001059 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:27 UTC |
HENDERSON JOHN TDirector
|
GrantCommon Stock | 434 | $48.93 | $21,235.62 |
DisclosureSEC source: 0001127602-25-000771 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,987 F1 · kind: Director Stock in Lieu of Cash Retainer Program Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:25 UTC |
Harrington Robert ArthurDirector
|
GrantCommon Stock | 255 | $48.93 | $12,477.15 |
DisclosureSEC source: 0001127602-25-000768 · form4.xml · nonDerivative · entry 1 Harrington Robert Arthur · CIK 0001923988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,008 F1 · kind: Director Stock in Lieu of Cash Retainer Program Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:25 UTC |
Kaye Edward M. MDDirector
|
GrantCommon Stock | 255 | $48.93 | $12,477.15 |
DisclosureSEC source: 0001127602-25-000765 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,637 F1 · kind: Director Stock in Lieu of Cash Retainer Program Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.